GERALD MURPHY: Open Payments
NPI 1376562462 · SAN FRANCISCO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$785 in 30 payments from 12 companies in 2025. Trend: 2023 $616 · 2024 $843 · 2025 $785
Food & beverage: $785
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $158 |
| GlaxoSmithKline, LLC. | 6 | $149 |
| PFIZER INC. | 3 | $86 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $79 |
| E.R. Squibb & Sons, L.L.C. | 2 | $75 |
| Novo Nordisk Inc | 3 | $73 |
| Lundbeck LLC | 2 | $49 |
| ABBVIE INC. | 1 | $29 |
| Lilly USA, LLC | 1 | $28 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $25 |
Products named: TRELEGY ELLIPTA, BREZTRI, ELIQUIS, JARDIANCE, AIRSUPRA, REXULTI, VYNDAQEL, QULIPTA.
Industry payments across CA — which companies pay providers there.
